tbuckley/cabot-search huggingface dataset:
Gonadal Function In Patients with Beta-Thalassemia Major Following Bone Marrow Transplantation,
Authors: Khalil Al Farsi, Murtadha K. Al-Khabori, Fehmida Zia, Moez Abdul-Rahim, Yusra Al-Habsi, Eman Al-Manthari, J. David Dennison, Shahina Daar
Journal: Blood (2011)
Abstract P4-21-34: Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
Authors: NM Iyengar, L Smyth, D Lake, A Gucalp, JC Singh, TA Traina, P DeFusco, MN Dickler, MN Fornier, S Goldfarb, K Jhaveri, S Modi, T Troso-Sandoval, D Argolo, K Jack, G Ulaner, M Jochelson, J Baselga, L Norton, CA Hudis, CT Dang
Journal: Cancer Research (2017)

Abstract Background: The combination of taxanes with trastuzumab (H) and pertuzumab (P) for first line treatment of HER2-positive metastatic breast cancer (MBC) is associated with improved progression-free survival (PFS) and overall survival (OS). Treatment per physician's choice with anti-HER2 therapy after second line therapy is associated with a median PFS of 3 months. While continued use of H in therapeutic combinations after progression on H-based therapy is common, the efficacy of continuing HP-based treatment after progression on P-based therapy is unknown. Methods: This is a single arm phase II trial of gemcitabine (G) with HP. Eligible patients had HER2-positive (IHC 3+ or FISH ≥ 2.0) MBC with prior HP-based treatment and ≤ 3 prior chemotherapies. Patients received G (1200 mg/m2) on days 1 and 8 of a q 3 week (w) cycle, and H (8 mg/kg load → 6 mg/kg) and P (840 mg load → 420 mg) q3w. The primary endpoint is PFS at 3 months. Secondary endpoints include OS, safety and tolerability. An exploratory endpoint is to compare PFS by RECIST criteria versus 18-F FDG-PET response criteria. Using a Simon optimal 2-stage design, 21 patients were enrolled in stage 1. The successful 3-month PFS rate for stage 1 was set at 57% to allow accrual to stage 2 for a total of 45 patients. The study therapy will be considered successful if at least 27/45 (60%) patients are progression free at 3 months. Results: As of June 9, 2016, 28 patients are enrolled; 21 are evaluable at 3 months and 7 have not had 3-month evaluation. At 3 months, 16/21 (76%) are progression free; 5 patients have progressed. The 3 month-PFS results for evaluable patients will be updated. There are no cardiac or febrile neutropenic events to date. Initially, 5 of 22 (23%) patients required G dose reduction (4 due to grade 3 neutropenia and 1 due to grade 3 vomiting) and the study was amended to lower initial G dose to 1000 mg/m2. Conclusions: The preliminary 3 month-PFS is 76% (95% CI 55% to 89%) in evaluable patients, and updated data will be presented. These findings suggest clinical benefit when P is continued beyond progression. Citation Format: Iyengar NM, Smyth L, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, Dickler MN, Fornier MN, Goldfarb S, Jhaveri K, Modi S, Troso-Sandoval T, Argolo D, Jack K, Ulaner G, Jochelson M, Baselga J, Norton L, Hudis CA, Dang CT. Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-34.
ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update
Authors: Manesh R. Patel, Gregory J. Dehmer, John W. Hirshfeld, Peter K. Smith, John A. Spertus
Journal: Journal of the American College of Cardiology (2012)
The squeeze test of MCP joints: a scarcity of scientific data, especially from primary care
Authors: A H M van der Helm-van Mil
Journal: Annals of the Rheumatic Diseases (2017)

The squeeze test of MCP joints: a scarcity of scientific data, especially from primary careWe thank Vega-Moralis et al 1 for their interest in the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis (RA). 2 The definition is composed of seven parameters and the authors are particularly interested in the parameter 'presence of a positive squeeze test of metacarpal joints'.They suggest that the squeeze test can be used in primary care to promote referral to secondary care, and they have developed an automated test. 1 First of all, we want to underline that the EULAR definition of arthralgia suspicious for progression to RA is developed for use in secondary care. 2 If the definition is also valuable for use in primary care needs to be determined.In addition, although the squeeze test is commonly used in daily practice, it is striking that there is not much scientific data on this test.A recent study performed in secondary care showed that the squeeze test of the MCP joints had a specificity >80%, but a low sensitivity. 3 To our knowledge, the performance of this test has never been studied in primary care.Although intuitively the squeeze test is believed valuable in decisions on referral, presently this is not supported by scientific data.There is also no evidence than an automated squeeze test performs better than manual squeezing of MCP joints.Although clinical evaluation is the basis of medicine, from many simple tests the test characteristics are insufficiently known.The squeeze test is an example that requires further studies, especially when the test is used in primary care.
A Phase 1 Trial of Cabazitaxel Combined With 188Re–Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment
Authors: Joyce M. van Dodewaard-de Jong, Esther W. Bouman-Wammes, Haiko J. Bloemendal, Henk M.W. Verheul, John M.H. de Klerk, Alfons J.M. van den Eertwegh
Journal: Clinical Nuclear Medicine (2017)

In patients with metastatic castration-resistant prostate cancer (mCRPC), bone-seeking radiopharmaceuticals, such as Re-hydroxyethylidene diphosphonate (HEDP), are effective for pain palliation and have a marked antitumor effect. Cabazitaxel is the standard second-line chemotherapy for mCRPC patients. We performed a phase 1 study investigating the safety and feasibility of the combined treatment with Re-HEDP and cabazitaxel in mCRPC patients.Patients with mCRPC and documented disease progression on or after docetaxel were eligible for inclusion. In both dose levels, cabazitaxel (4 cycles of cabazitaxel 25 mg/m + 2 cycles of cabazitaxel 20 mg/m in level 1, and 6 cycles of cabazitaxel 25 mg/m in level 2) were combined with 2 cycles of Re-HEDP 40 MBq/kg (1.1 mCi/kg) (after the second and fourth cabazitaxel cycles). Three patients were planned for each dose level, expanding to 6 patients in case of a dose-limiting toxicity (DLT). A DLT is defined as any grade 4 toxicity, or grade 3 toxicity delaying the next treatment cycle.Twelve patients were included, of whom 3 had progressive disease before the third cycle of cabazitaxel. In total, 1 DLT occurred (dose level 1) after treatment cycle 6 (Re-HEDP) (thrombopenia grade 3 delaying the next treatment cycle). The cohort was expanded to 6 patients, with no further DLTs. No DLT occurred in dose level 2. The most important adverse events were of hematologic origin, followed by mild fatigue and diarrhea.Combination therapy with cabazitaxel and Re-HEDP is feasible and generally well tolerated with similar hematologic toxicity compared with cabazitaxel monotherapy.
JAK1/2 Inhibition As a Salvage Therapy for Steroid Refractory Acute and Chronic Graft Versus Host Disease in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients
Authors: Pooja Khandelwal, Ashley Teusink-Cross, Adam S. Nelson, Christopher E. Dandoy, Javier A. El-Bietar, Rebecca A Marsh, Ashish R Kumar, Michael S Grimley, Sonata Jodele, Stella M Davies, Kasiani C. Myers
Journal: Blood (2016)
AB1042 Patient Beliefs Regarding Associations between Weather and Pain; An Analysis of Enrolment Questionnaires within “Cloudy with A Chance of Pain”:
Authors: R. Patel, J. Sergeant, J. McBeth, D. Schultz, C. Sanders, L. Cook, J. Ainsworth, W. Dixon
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The association between the weather and chronic pain is complex and largely undetermined. More than 80% of patients believe in an association between weather and pain. However, beliefs vary about which weather variable (e.g. temperature, atmospheric pressure) influences pain, with possible differences across pain disorders. <h3>Objectives</h3> To describe participants9 beliefs about an association between weather and pain at the time of enrolment to a national smartphone study entitled "Cloudy with a Chance of Pain", stratified by self-reported diagnosis. <h3>Methods</h3> Participants in the UK aged 17 years or older, with access to a smartphone and who had arthritis or other chronic pain for at least 3 months were recruited to "Cloudy with a Chance of Pain". Participants completed an 8 point enrolment questionnaire which included two questions about their beliefs: 1) Belief strength: On a scale of 0–10, how likely do you think weather is associated with pain? 2) Belief type: If you think there is a possible association, which weather condition(s) affect your pain the most? Both questions offered categorical response options. In question 2, participants were permitted to select multiple categories and a "free text" option was also offered. We present a descriptive analysis of the categorical data and sub-analyses of differential beliefs by age (above/below 50yrs), gender and self-reported diagnosis. Results are reported as median (IQR) or number (%). Mann-Whitney U-Test and Fisher9s exact test were used for statistical analysis. Within Table 1, significant associations (p&lt;0.05) are denoted by bold text. <h3>Results</h3> 5,282 enrolment questionnaires were included in analysis. Median belief strength was 7 (5–9). 8% reported a belief strength of 4 or less. Participants most commonly believed that "damp/rain" affected their symptoms (72%). When compared to the total study population, those with fibromyalgia, chronic headache and neuropathic pain more frequently believed that changes in temperature and pressure correlated with pain. Indeed, participants with fibromyalgia and neuropathic pain more commonly reported belief in an association between all aspects of weather and pain when compared to the total study population. Table 1 summarises belief strength and belief type by gender, age and underlying diagnosis. <h3>Conclusions</h3> Most participants strongly believed in an association between weather and pain. Participants most commonly believed that damp/rain affected their pain. Specific beliefs vary between participants and between diagnostic groups, perhaps reflecting different causal pathways in these conditions. <h3>Acknowledgement</h3> Arthritis Research UK and uMotif Ltd. <h3>Disclosure of Interest</h3> None declared
OP12. BRAIN UK, THE NATIONAL BRAIN TUMOUR BANK NETWORK THREE YEARS ON
Authors: Dr Clare Mitchell, Dr Helen Bulbeck, Dr Kathreena M Kurian, Dr David Hilton, Prof James AR Nicoll
Journal: Neuro-Oncology (2017)

INTRODUCTION: Brain tumour tissue can be difficult for researchers to access, yet National Health Service (NHS) Neuropathology archives contain a wealth of tissue. A review of NHS CNS biopsy archives revealed around 400,000 stored samples, accruing a further 18,500 annually. Simply trying to identify suitable tissue to help shape a study can pose challenges. In addition, the legal and ethical considerations required for approval to use human tissue can be difficult to new researchers and can prove time consuming. METHOD: BRAIN UK is a collaborative national virtual brain bank, facilitating access to under-utilised neuropathology archives for research. Initially funded by the MRC to facilitate access to post-mortem archives and two and half years ago expanded to include biopsies; supported by a group of brain tumour charities led by the brainstrust. 27/30 NHS Neuropathology centres and the Corsellis Collection participate in BRAIN UK, giving effective coverage of over 90% of UK population. A linked-anonymised database includes diagnosis and simple demographics. There is a centralised application process www.brain-uk.org. BRAIN UK acts as a “matchmaker” and its generic ethical approval covers the majority of projects. Investigators’ grants fund the costs associated with the retrieval, processing and transportation of tissue. RESULTS: BRAIN UK utilises its generic ethical approval to reduce the time for researchers to achieve ethics; its network to obtain tissue; and its expertise and insight into potentially available tissue to help form scientifically valid studies. 26 tumour applications and 12 informal enquiries have been supported with over 3,000 tissue samples approved for release for research. Studies have encompassed a wide variety of tumour types utilising a number of techniques. Studies utilising large quantities or rare tumour types particularly highlight the success of this approach. CONCLUSION: Archived tissue that would otherwise be unused has supported valuable research. BRAIN UK is completely reliant on the co-operation and support of its Participating Centres. With plans to include a collaboration with UK Biobank, facilitating access to data, and encourage collaborations, BRAIN UK is advancing in to the future with aims to add value to neuroscience research.
OP22. MODELLING THE FATE OF INTERSTITIALLY DELIVERED THERAPIES TO BRAIN MALIGNANCIES
Authors: Dr Toby Gould, Mr Lee Curtin, Dr Stuart Smith, Dr Kristoffer Van Der Zee, Prof Markus Owen, Prof Richard Grundy, Dr Ruman Rahman
Journal: Neuro-Oncology (2017)

Advances in therapy delivery systems are providing new opportunities for the treatment of malignancies of the central nervous system. There is opportunity for locally administered therapies that overcome the Blood Brain Barrier (BBB) to be implanted at the point of tumour resection surgery into or around the cavity left behind. This is particularly the case for Glioblastoma Multiforme (GBM). The pharmacodynamics of a therapy delivered in this way into brain tissue is of key importance to optimizing these therapies as the correct dose reaching the micro-deposits of malignant cells unreachable by surgery is thought to be key in slowing disease progression. We examine the particular case of a drug loaded poly(lactic-co-glycolic acid)/poly(ethylene-glycol) (PLGA/PEG) polymer particle paste designed to release drug to surrounding brain tissue post surgical implantation. By experimentally parameterizing the distribution, release and uptake kinetics we have modeled the biodistribution of methotrexate conjugated to a fluorescent moiety fluorescein isothiocyanate (FITC). We have also used micro-computerized tomography (µ-CT) to determine the microstructure of the PLGA/PEG construct and assess how the drug progresses out from the interior of the construct. The model consists of a system of reaction-diffusion equations describing the time evolution of spatially dependent concentrations of a drug in three different materials: normal brain tissue, cerebrospinal fluid (CSF) and the PLGA/PEG implant, each have their own diffusion tensors that describe the anisotropy of the brain. The model was built upon simple one-dimensional time course experiments measuring the rate at which a drug molecule can pass through a standardized volume of PLGA/PEG paste and the rate at which the drug is taken up by brain tissue. We simulated computationally a gap of CSF between the PLGA/PEG construct and the brain tissue to ascertain whether good tissue apposition was key to drug delivery. Known release rates of drugs from previous studies were also fitted to the model, allied to this their known logD values were used to test the model. We have been able to see that the chemical properties of the compounds studied, in particular the logD values, have a great effect on the simulated release, passage across the CSF and uptake in the brain tissue. Hence not having a CSF barrier between Allying these drug release and distribution models to models of tumour growth, the interaction of the polymer with the tissue and the polymer and the drug we aim to better select drugs according to chemical properties, simulate repurposed drugs and predict drug coverage where it is required to improve the control of GBM as a disease.
Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).
Authors: Naomi Winick, Paul L. Martin, Meenakshi Devidas, Jonathan Shuster, Michael J. Borowitz, Paul Bowman, Eric Larsen, Jeanette Pullen, Stephen P. Hunger, William L. Carroll, Bruce M. Camitta
Journal: Blood (2007)
Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD
Authors: T Yuan, Y Yang, J Chen, W Li, W Li, Q Zhang, Y Mi, R S Goswami, J Q You, D Lin, M D Qian, S Calin, Y Liang, R N Miranda, G A Calin, X Zhou, L Ma, P A Zweidler-McKay, B Liu, A P Weng, L J Medeiros, Y Zhang, M J You
Journal: Leukemia (2017)
Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.
Authors: Gabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, Massimo Breccia, Luciano Levato, Fabio Stagno, Giovanna Rege-Cambrin, Alfonso Zaccaria, Giorgina Specchia, Emilio Usala, Antonella Gozzini, Bruno Martino, Adele Capucci, Pellegrino Musto, Mario Tiribelli, Elisabetta Abruzzese, Simona Soverini, Maria Teresa Bochicchio, Nicoletta Testoni, Giuseppe Saglio, Giovanni Martinelli, Fabrizio Pane, Giuliana Alimena, Michele Baccarani, Gianantonio Rosti
Journal: Blood (2012)
Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions
Authors: Erika F Duffell, Dagmar Hedrich, Otilia Mardh, Antons Mozalevskis
Journal: Eurosurveillance (2017)

The World Health Organization ‘Global Health Sector Strategy on Viral Hepatitis 2016–2021’ aimed at the elimination of viral hepatitis as a public health threat provides a significant opportunity to increase efforts for tackling the epidemics of hepatitis B and hepatitis C virus infections across Europe. To support the implementation and monitoring of this strategy, core epidemiological and programmatic indicators have been proposed necessitating specific surveys, the systematic collection of programmatic data and the establishment of monitoring across the care pathway. European Union and European Economic Area countries already made progress in recent years implementing primary and secondary prevention measures. Indeed, harm reduction measures among people who inject drugs reach many of those who need them and most countries have a universal hepatitis B vaccination programme with high coverage above 95%. However, while a further scaling up of prevention interventions will impact on incidence of new infections, treating those already infected is necessary to achieve reductions in mortality. The epidemiological, demographic and socio-political situation in Europe is complex, and considerable diversity in the programmatic responses to the hepatitis epidemic exists. Comprehension of such issues alongside collaboration between key organisations and countries will underpin any chance of successfully eliminating hepatitis.
Low Dose Busulfan and ATG with Fludarabine as Conditioning Regimen Was Effective in Sibling and Unrelated Donor HSCT in CML Patients.
Authors: Andrzej Lange, Mariola Sedzimirska, Dorota Dlubek, Emilia Jaskula, Anna Mlynarczewska, Agnieszka Sok
Journal: Blood (2006)
Telmisartan, Angiotensin II Receptor Blocker, Induces Apoptosis and Autophagy in Adult T-Cell Leukemia Cells from Patients and Leukemia Cell Lines
Authors: Tomohiro Kozako, Makoto Yoshimitsu, Naomichi Arima, Shuhei Soeda, Shinya Hirata, Hiroaki Tanaka, Shin-ichiro Honda, Shinji Soeda
Journal: Blood (2015)
WORLDWIDE VARIATION IN THE USE OF NUCLEAR CARDIOLOGY CAMERA TECHNOLOGY, RECONSTRUCTION SOFTWARE, AND ACQUISITION PROTOCOLS: FINDINGS FROM THE IAEA NUCLEAR CARDIOLOGY PROTOCOLS STUDY (INCAPS)
Authors: Edward A. Hulten, Mathew Mercuri, Thomas Pascual, Joao Vitola, Nathan Better, Ganesan Karthikeyan, John Mahmarian, Madan Rehani, Maurizio Dondi, Diana Paez, Andrew Jeffrey Einstein
Journal: Journal of the American College of Cardiology (2017)
IMPLANTABLE CARDIOVERTER DEFIBRILLATOR FOR THE PREVENTION OF MORTALITY IN NON-ISCHEMIC CARDIOMYOPATHY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Mohit Turagam, Poonam Velagapudi, Venkat Vuddanda, Valay Parikh, Mohammad-Ali Jazayeri, Madhav Lavu, Tushar Tarun, Kul Aggarwal, Donita Atkins, Sudharani Bommana, Luigi Di Biase, Andrea Natale, Dhanunjaya Lakkireddy, Madhu Reddy
Journal: Journal of the American College of Cardiology (2017)
Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism
Authors: Mark A. Crowther, Adam Cuker
Journal: New England Journal of Medicine (2017)

Warfarin and direct oral anticoagulant agents prevent recurrent venous thromboembolism. When a first episode of venous thromboembolism occurs in association with a transient risk factor (e.g., surgery), treatment can be stopped after 3 months. With persistent and strong risk factors, such as cancer, therapy should be continued indefinitely.1 Prolonged anticoagulation therapy is now suggested for most patients with unprovoked venous thromboembolism. Cessation of therapy after 3 to 6 months may be recommended in some female patients who are judged to be at low risk for recurrence,2 in patients at high risk for bleeding, and in patients with poor adherence or . . .